Drs Bekaii-Saab, George, and von Mehren discuss patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2 study investigating DCC-3116 in patients with RAS or RAF–mutated solid tumors, and how vimseltinib may alleviate unmet needs in the tenosynovial giant cell tumors population.
Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Deciphera, we had the pleasure of speaking with Tanios S. Bekaii-Saab, MD; Suzanne George, MD, and Margaret von Mehren, MD.
Bekaii-Saab is the medical director of the Cancer Clinical Research Office and the vice chair and section chief for medical oncology in the Department of Internal Medicine at the Mayo Clinic, as well as the leader of the Gastrointestinal Cancer Program at the Mayo Clinic Comprehensive Cancer Center. George is a senior physician and the director of Clinical Research in the Sarcoma Center at Dana-Farber Cancer Center, as well as an associate professor of medicine at Harvard Medical School. von Mehren is chief of the division of sarcoma medical oncology, vice chair of the Department of Hematology/Oncology, physician director of the Clinical Trials Office, and associate director of Clinical Research at Fox Chase Cancer Center.
In our exclusive interview, Drs Bekaii-Saab, George, and von Mehren discussed key efficacy data and patient-reported outcomes regarding tolerability from the phase 3 INTRIGUE trial (NCT03673501), which evaluated ripretinib (Qinlock) vs sunitinib (Sutent) in patients with advanced gastrointestinal stromal tumors (GIST) who were previously treated with imatinib (Gleevec). Dr Bekaii-Saab also shared the rationale for a phase 1/2 study (NCT04892017) investigating the novel ULK inhibitor DCC-3116 alone or in combination with trametinib (Mekinist) in patients with advanced or metastatic RAS or RAF–mutated solid tumors. Additionally, Drs George and von Mehren highlighted how vimseltinib (DCC-3014), which is being investigated in tenosynovial giant cell tumors (TGCT) in the phase 3 MOTION trial (NCT05059262), could alleviate unmet needs in the TGCT population.
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by Deciphera. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.